YUPELRI (revefenacin)
Yupelri is a long-acting medication used for the daily maintenance of chronic obstructive pulmonary disease (COPD). It helps patients with this condition by providing ongoing support to keep the airways open and improve breathing. This anticholinergic therapy is prescribed as a regular treatment to help manage the persistent respiratory symptoms associated with chronic lung disease.
How YUPELRI Works
This medication works by blocking M3 receptors found in the smooth muscles of the airways. By inhibiting these receptors, the drug relaxes the muscles and causes bronchodilation, which helps prevent the lungs from tightening. This site-specific effect is long-lasting, providing relief from airway constriction for more than 24 hours.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2018-11-09
- Patent Cliff
- 2039
- Routes
- INHALATION
- Dosage Forms
- SOLUTION
YUPELRI Approval History
What YUPELRI Treats
1 indicationsYUPELRI is approved for 1 conditions since its original approval in 2018. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Chronic Obstructive Pulmonary Disease
YUPELRI Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to YUPELRI
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
3 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT05165485 PIFR-2 results posted | 0180 | Ph 4 | completed | Phase 4 COPD and Suboptimal Inspiratory Flow Rate |
| NCT03095456 results posted | 0149 | Ph 3 | completed | Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD |
| NCT03573817 results posted | 0167 | Ph 3 | completed | A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
YUPELRI FDA Label Details
Indications & Usage
FDA Label (PDF)YUPELRI is indicated for the treatment of Chronic Obstructive Pulmonary Disease.
YUPELRI Patents & Exclusivity
Patents (10 active)
Pro Intelligence Preview
Deep insights for YUPELRI
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2039
- • 10 active patents
Trial Analysis
- • 3 total trials
- • Stage: Declining
Competitive Landscape
- • 20 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment